Antibody constructs for CD70 and CD3

US10851170B2 · kind B2 · utility

Assignees

• AMGEN RESEARCH (MUNICH) GMBH · DE
• AMGEN INC. · US

Inventors

• Tobias Raum · Munich, DE
• Claudia Blümel · Munich, DE
• Wibke Deisting · Munich, DE
• Patrick Hoffmann · Munich, DE
• Ralf Lutterbüse · Munich, DE
• Elisabeth Nahrwold · Munich, DE
• Olivier Nolan-Stevaux · Millbrae, US
• Marc Panzer · Munich, DE

Key dates

• Filing date: Aug 1, 2016
• Grant date: Dec 1, 2020
• Expiry date: Aug 1, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.